What is the price target for CRIS stock?
11 analysts have analysed CRIS and the average price target is 14.28 USD. This implies a price increase of 1730.77% is expected in the next year compared to the current price of 0.78.
NASDAQ:CRIS • US2312693094
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for CURIS INC (CRIS).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2025-03-31 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-12-10 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-01 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-09-27 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-01 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-15 | Cantor Fitzgerald | Reiterate | Overweight |
| 2024-05-15 | Truist Securities | Maintains | Buy -> Buy |
| 2024-05-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-08 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-02-09 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-11-17 | Truist Securities | Initiate | Buy |
| 2023-09-29 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-09-25 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-09-07 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2023-08-04 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-07-11 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2023-07-07 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-05-05 | HC Wainwright & Co. | Reiterate | Buy |
| 2022-11-10 | HC Wainwright & Co. | Maintains | Buy |
| 2021-10-13 | Raymond James | Initiate | Outperform |
| 2021-03-25 | B. Riley FBR | Initiate | Buy |
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 10.16M -4.60% | 10.023M -1.35% | 10.908M 8.83% | 11.577M 6.13% | 12.487M 7.86% | 20.846M 66.94% | 45.73M 119.37% | 95.472M 108.77% | 133.98M 40.33% | 160.96M 20.14% | 188.39M 17.04% | 218.33M 15.89% | |
| EBITDA YoY % growth | -52.79M -25.96% | -48.077M 8.93% | -44.339M 7.78% | -35.394M 20.17% | -39.882M -12.68% | -80.458M -101.74% | -42.167M 47.59% | -44.115M -4.62% | -55.233M -25.20% | -53.101M 3.86% | -47.858M 9.87% | N/A | |
| EBIT YoY % growth | -53.02M -26.03% | -48.332M 8.84% | -44.542M 7.84% | -33.808M 24.10% | -37.478M -10.85% | -37.594M -0.31% | -25.67M 31.72% | 2.55M 109.93% | 28.05M 1,000.00% | 50.49M 80.00% | 72.42M 43.43% | 96.39M 33.10% | |
| Operating Margin | -521.85% | -482.21% | -408.34% | -292.03% | -300.14% | -180.34% | -56.13% | 2.67% | 20.94% | 31.37% | 38.44% | 44.15% | |
| EPS YoY % growth | -12.20 -22.00% | -8.96 26.56% | -7.03 21.54% | -2.60 63.06% | -1.83 29.54% | -1.12 38.82% | -0.61 45.33% | -0.40 35.00% | -0.03 92.31% | 0.52 1,800.00% | 1.07 105.88% | 1.63 52.38% |
All data in USD
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.46 63.28% | -0.40 67.77% | -0.34 49.75% | -0.32 34.43% | -0.33 27.78% |
| Revenue Q2Q % growth | 3.253M -2.75% | 2.856M 20.00% | 3.06M 11.31% | 3.366M 5.98% | 3.366M 3.47% |
| EBITDA Q2Q % growth | -9.486M -7.91% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -7.47M 16.94% | -8.772M 13.64% | -8.772M -6.31% | -9.792M -41.42% | -11.067M -48.15% |
All data in USD
11 analysts have analysed CRIS and the average price target is 14.28 USD. This implies a price increase of 1730.77% is expected in the next year compared to the current price of 0.78.
CURIS INC (CRIS) will report earnings on 2026-03-30, after the market close.
The consensus EPS estimate for the next earnings of CURIS INC (CRIS) is -0.46 USD and the consensus revenue estimate is 3.25M USD.
The number of analysts covering CURIS INC (CRIS) is 11.